Robert W. Baird Has Lowered Expectations for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price target decreased by equities research analysts at Robert W. Baird from $212.00 to $210.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s target price would indicate a potential upside of 6.46% from the stock’s current price.

A number of other analysts also recently issued reports on the company. Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Wednesday, December 11th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Stock Performance

Shares of IQVIA stock opened at $197.25 on Tuesday. The business has a 50-day simple moving average of $200.09 and a 200-day simple moving average of $221.39. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA has a one year low of $187.62 and a one year high of $261.73. The company has a market cap of $35.80 billion, a PE ratio of 25.89, a P/E/G ratio of 2.01 and a beta of 1.48.

Institutional Trading of IQVIA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp acquired a new stake in IQVIA in the third quarter valued at approximately $28,000. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Assetmark Inc. boosted its holdings in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. grew its position in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.